Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.74 |
| ▸ | NPY5R | Q15761 | 13/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.54 |
| ▸ | NPY2R | P49146 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3447214 | 1.00 | GAA (0.74) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL6223855 | 1.00 | GAA (0.74) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL26707660 | 1.00 | GAA (0.74) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL3447213 | 1.00 | GAA (0.74) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL8285851 | 0.85 | GAA (1.00) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL13893334 | 0.85 | GAA (0.72) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL9907064 | 0.85 | GAA (0.72) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL8728635 | 0.85 | GAA (0.72) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL8561317 | 0.85 | GAA (1.00) | GAANPY5RKDM4EALDH1A1AOC3 | |
| SCHEMBL879389 | 0.85 | GAA (1.00) | GAANPY5RKDM4EALDH1A1AOC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | JANSSEN PHARMACEUTICA NV (BE) | 2023-12-28 | — | — | US | disclosed |
| EP-4225757-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | Bristol-Myers Squibb Company (US) | 2023-08-16 | — | — | EP | disclosed |
| WO-2022081473-A1 | A PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}-1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B] [1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-04-21 | — | — | WO | disclosed |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | UNIV YALE (US) | 2017-10-26 | — | — | US | disclosed |
| US-9632089-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2017-04-25 | — | — | US | disclosed |
| US-9632089-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2017-04-25 | — | — | US | disclosed |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-09 | — | — | US | disclosed |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-09 | — | — | US | disclosed |
| US-9500653-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-9500653-B2 | Small-molecule hydrophobic tagging of fusion proteins and induced degradation of same | YALE UNIVERSITY (US) | 2016-11-22 | — | — | US | disclosed |
| US-20140302523-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | YALE UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| US-20140302523-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | YALE UNIVERSITY (US) | 2014-10-09 | — | — | US | disclosed |
| WO-2014108526-A1 | SYNTHETIC PROCESS FOR THE MANUFACTURE OF PIPECOLIDEPSIN COMPOUNDS | PHARMA MAR, S.A. (ES) | 2014-07-17 | — | — | WO | disclosed |
| US-7354919-B2 | Isoxazole compositions useful as inhibitors of ERK | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-08 | — | — | US | disclosed |
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | F. HOFFMANN-LA ROCHE AG (CH) | 2004-04-22 | — | — | US | disclosed |
| EP-0751927-A4 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INST OF TECHN (US) | 1998-07-29 | — | — | EP | disclosed |
| EP-0751927-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1997-01-08 | — | — | EP | disclosed |
| US-5488131-A | Synthesis of compounds with predetermined chirality | CALIFORNIA INSTITUTE OF TECHNOLOGY | 1996-01-30 | — | — | US | disclosed |
| WO-1995025714-A1 | SYNTHESIS OF COMPOUNDS WITH PREDETERMINED CHIRALITY | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 1995-09-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040077728-A1 | Retiferol derivatives and their use in the treatment of skin diseases or conditions associated with photodamage | NR1H2, RFC2, RFC1 | GAA 4070/4885NPY5R 942/4885KDM4E 1276/4885 |
| US-20230416252-A1 | PROCESS TOWARD THE MANUFACTURE OF (6R,10S)-10-{4-[5-CHLORO-2-(4-CHLORO-1H-1,2,3-TRIAZOL-1-YL)PHENYL]-6-OXO-1(6H)-PYRIMIDINYL}- 1-(DIFLUOROMETHYL)-6-METHYL-1,4,7,8,9,10-HEXAHYDRO-11,15-(METHENO)PYRAZOLO[4,3-B][1,7]DIAZACYCLOTETRADECIN-5(6H)-ONE | CYP1B1, AZI2, TET1 | GAA 2145/4885NPY5R 1907/4885KDM4E 689/4885 |
| US-20170067874-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | GAA 532/4885NPY5R 4726/4885KDM4E 3911/4885 |
| US-20170307614-A1 | Small-Molecule Hydrophobic Tagging of Fusion Proteins and Induced Degradation of Same | HSP90B1, LAMP2, PSMG3 | GAA 538/4885NPY5R 4732/4885KDM4E 3832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.